英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
appendre查看　appendre　在百度字典中的解释百度英翻中〔查看〕
appendre查看　appendre　在Google字典中的解释Google英翻中〔查看〕
appendre查看　appendre　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Treatment for Advanced CSCC | LIBTAYO® (cemiplimab-rwlc)
    A therapy for adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation
  • FDA Approves Immunotherapy for Cutaneous Squamous-cell Carcinoma
    THE FOOD AND DRUG ADMINISTRATION (FDA) approved the immunotherapy Libtayo (cemiplimab) for high-risk cutaneous squamous-cell carcinoma (CSCC), a common skin cancer type The Oct 8, 2025, approval was based on findings that people given Libtayo after surgery and radiation lived longer without their disease recurring—a measure known as disease-free survival—compared with those treated with
  • What Libtayo Means for High-Risk Cutaneous Squamous Cell . . .
    Key Takeaways Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing recurrence risk by 68% in the C-POST trial Administered post-surgery and radiation, Libtayo prevents recurrence rather than treating existing tumors, with a safety profile consistent with advanced cancer use
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . .
    Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    Libtayo® (cemiplimab-rwlc) Approved in the U S as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
  • Adjuvant Cemiplimab Approval Redefines Management of High . . .
    Libtayo (cemiplimab-rwlc) approved in the U S as first and only immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) with a high risk of recurrence after surgery and
  • Libtayo® Gains FDA Approval as First Adjuvant PD-1 Therapy . . .
    The FDA has approved cemiplimab-rwlc (Libtayo®) for adjuvant treatment of adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation Libtayo is already approved for advanced CSCC, basal cell carcinoma, and NSCLC
  • Libtayo First PD-1 Inhibitor Treatment for Cutaneous Squamous . . .
    The U S Food and Drug Administration (FDA) approved Libtayo (cemiplimab, REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma





中文字典-英文字典  2005-2009